Home›The Library›Lucinactant
Lucinactant (Surfaxin)
Lucinactant was the first FDA-approved surfactant drug built around a synthetic peptide (KL4/sinapultide) rather than one extracted from animal lungs — a real, evidence-backed 2012 approval for a genuine unmet need in premature infants. It's also a real example of a drug that succeeded scientifically and still failed commercially: its maker stopped selling it in 2015, for competitive and manufacturing reasons, not a safety or efficacy problem.
On this page
In brief
Should you care? Mostly for what it represents — a rare, well-documented case of a synthetic peptide drug that won FDA approval on real evidence and still couldn't survive commercially against older, animal-derived competitors.The short version
- KL4 (sinapultide) is a 21-amino-acid synthetic peptide designed to mimic human surfactant protein B, combined with phospholipids to lower surface tension in an infant's lungs.
- FDA-approved in March 2012 as Surfaxin, the first synthetic peptide-containing lung surfactant, for preventing respiratory distress syndrome in premature infants.
- Withdrawn from commercial sale in 2015 by its maker — a business decision against entrenched animal-derived competitors, not a safety finding.
What it is
Premature infants can lack enough of their own pulmonary surfactant — the substance that keeps the tiny air sacs in the lungs from collapsing on each exhale — causing respiratory distress syndrome (RDS), a leading cause of complications and death in premature birth. Older surfactant drugs (beractant, poractant alfa, calfactant) are extracted from cow or pig lungs. Lucinactant instead pairs synthetic phospholipids with KL4 (sinapultide), a 21-amino-acid synthetic peptide (four repeats of a lysine/tetraleucine motif) engineered to mimic the function of human surfactant protein B without needing an animal source.
The 2012 approval
The FDA approved lucinactant, marketed as Surfaxin by Discovery Laboratories, on 6 March 2012, for the prevention of respiratory distress syndrome in premature infants at high risk for RDS — the first synthetic, peptide-containing surfactant drug ever approved, an alternative to the animal-derived options that had dominated the category since the 1990s.
Why it isn't sold anymore
Discovery Laboratories stopped commercial distribution of Surfaxin in 2015. This was a business decision, not a withdrawal for safety or efficacy reasons: the company struggled to compete against well-established, already-trusted animal-derived surfactants in a small, specialized neonatal-ICU market, and shifted its strategic focus toward an aerosolized, non-invasive delivery version of the same KL4 peptide (branded Aerosurf) that could avoid the need for intubation altogether — a genuinely different value proposition from competing head-to-head as another instilled surfactant.
Where the peptide platform stands now
The company behind Surfaxin, renamed Windtree Therapeutics, continued developing the same KL4 peptide platform in aerosolized and other investigational forms — including a completed Phase 2 trial of lucinactant for COVID-19-associated acute respiratory distress syndrome in adults, a use well outside the original premature-infant indication. Windtree has since licensed the KL4/Aerosurf platform's further clinical development globally to Lee's Pharmaceutical (Hong Kong) rather than continuing it directly, and no KL4-based product is currently FDA-approved or commercially marketed in the US — the platform remains investigational, not a return to market. Worth knowing separately: Windtree Therapeutics itself was delisted from Nasdaq in August 2025 after an unrelated, unsuccessful pivot toward a cryptocurrency-treasury strategy — a real signal about the parent company's financial stability, distinct from any question about the KL4 science itself.
References
- FDA approval of Surfaxin (lucinactant), 6 March 2012 (Discovery Laboratories) — first synthetic, peptide-containing pulmonary surfactant approved for prevention of respiratory distress syndrome in premature infants.
- Discovery Laboratories/Windtree Therapeutics public statements and SEC filings on ceasing Surfaxin commercial distribution in 2015 and shifting strategic focus to Aerosurf (aerosolized KL4 surfactant).
- Windtree Therapeutics, Phase 2 trial results, lucinactant for COVID-19-associated acute respiratory distress syndrome (ClinicalTrials.gov NCT04389671), and the global KL4/Aerosurf licensing arrangement with Lee's Pharmaceutical (Hong Kong); Nasdaq delisting notice, Windtree Therapeutics, August 2025.